• Vivet Therapeutics

    Vivet Therapeutics
    raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

     Read More
  • Transforming Lives

    Transforming Lives
    Novel gene therapies for rare, inherited metabolic diseases

     Read More
  • Wilson’s Disease

    Wilson’s Disease
    Benefits of AAV gene therapy as a novel approach to manage Wilson’s disease

     Read More
Gene Therapy Programs Gene Therapy Programs

A dedicated platform for the development of innovative treatments for inherited liver diseases in collaboration with CIMA based on AAV-Anc80 from MEE
Product Pipeline Product Pipeline

Targeting life threatening and severely debilitating liver metabolic disorders with high unmet medical need in pediatric and adult patients
Wilson's Disease Wilson's Disease

Development of a high-activity ATP7B transgene paves the way towards restoring normal copper metabolism in Wilson’s disease patients through gene therapy

Welcome to Vivet Therapeutics

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases.

Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra)  to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Latest News